Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 8/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 6/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7425561 | 0.73 | PDE4B (0.50) | PDE4DPDE4BGFERPDE4APDE4C | |
| SCHEMBL7474586 | 0.71 | PDE4B (0.50) | PDE4DPDE4BGFERPDE4APDE4C | |
| SCHEMBL7417915 | 0.71 | PDE4B (0.52) | PDE4DPDE4BGFERPDE4APDE4C | |
| SCHEMBL15532207 | 0.70 | PDE4B (0.69) | PDE4DPDE4BGFERPDE4APDE4C | |
| SCHEMBL9526223 | 0.69 | PDE4B (0.68) | PDE4DPDE4BGFERPDE4APDE4C | |
| SCHEMBL30614148 | 0.67 | PDE4D (0.68) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL7542303 | 0.67 | GFER (0.48) | PDE4DPDE4BGFERPDE4APDE4C | |
| SCHEMBL8122449 | 0.66 | TYK2 (0.71) | JAK2TYK2 | |
| SCHEMBL6833145 | 0.66 | PDE4D (0.65) | PDE4DPDE4BGFERPDE4APDE4C | |
| SCHEMBL14532456 | 0.65 | PDE4B (0.49) | PDE4DPDE4BGFERPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242146-B2 | Administering ROFLUMILAS and DICLOFENAC; antiinflammatory agents | NYCOMED GMBH (DE) | 2012-08-14 | — | — | US | claimed |
| US-20080255209-A1 | Combination of a NSAID and a PDE-4 inhibitor | NYCOMED GMBH (DE) | 2008-10-16 | — | — | US | claimed |
| US-20060079540-A1 | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia | ALTANA PHARMA AG (DE) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079540-A1 | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia | PDE4A, PDE12, PDE4B | PDE4D 8/4885PDE4B 3/4885GFER 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.